Results from TALAPRO-2: increased survival in metastatic castration resistant prostate cancer beyond HRR mutations (BRCA, ATM,...)

[Maxone73]

I think I have already posted about this...but I am on ADT so I have a good excuse to repeat myself!

Trial results are from the last year, but based on these results, they are trying to push this combo to be used also when no HRR mutation is present:

"In the final rPFS analysis, TALZENNA plus XTANDI reduced the risk of disease progression or death by 37% versus placebo plus XTANDI (Hazard Ratio [HR]: 0.63; 95% Confidence Interval [CI], 0.51–0.78; P< 0.001). The median rPFS for the treatment arm was not reached at the time of analysis versus 21.9 months for placebo plus XTANDI. Median rPFS is reached when 50% of trial participants have had an event of disease progression or death."

I am curious to see if the results will move along the lines of the BRCAAWAY trial, but that median rPFS looks quite good!

biospace.com/drug-developme...

[GP24]

I think the results are driven by the subgroup of included BRCA positive patients.

[j-o-h-n]

"so I have a good excuse to repeat myself!" What?

Good Luck, Good Health and Good Humor.

j-o-h-n

[MarylandGuy]

how does this compare to Lynparza?

[Maxone73 in reply to MarylandGuy]

The only real "selling point" I can see at the moment is the fact that Talzenna has a statistically meaningful effect also on non genetically mutated patients. Lynparza works very well on BRCA mutations only, has little effect on ATM and no effect on the general population. I am curious to see the outcomes from the trial of a second generation PARP1 inhibitor that should work way better than both talzenna and lynparza.